Drugs / TCR gene-transduced PBLs
TCR gene-transduced PBLs
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00091104 | Jul 2004 → Aug 2010 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR gene-transduced PBLs | “Patients also receive autologous in vitro tumor-reactive, T-cell receptor (TCR) gene-transduced PBLs IV over 20-30 minutes on day 1” NCT00091104 ↗ |
| Known as | PBLs | “Determine the safety of peripheral blood lymphocytes (PBLs) retrovirally transduced with an anti-MART-1 T-cell receptor (TCR) gene” NCT00091104 ↗ |
| Known as | peripheral blood lymphocytes | “Determine the safety of peripheral blood lymphocytes (PBLs) retrovirally transduced with an anti-MART-1 T-cell receptor (TCR) gene” NCT00091104 ↗ |
| Modality | Cell therapy | “gene-modified white blood cell infusions” NCT00091104 ↗ |
| Route | Intravenous | “T-cell receptor (TCR) gene-transduced PBLs IV over 20-30 minutes” NCT00091104 ↗ |